Katarzyna Wiklik

Title: **Innovator Spotlight: Katarzyna Wiklik**

Introduction

Katarzyna Wiklik, based in Kraków, Poland, is an accomplished inventor with a focus on developing innovative pharmaceutical solutions. With a strong background in medicinal chemistry, she has made significant contributions to the field, particularly through her patented inventions that target various diseases through kinase inhibition.

Latest Patents

Katarzyna Wiklik holds three patents, the latest of which include:

1. **Benzimidazole derivatives as kinase inhibitors** - This invention relates to derivatives of benzimidazoles, showcasing their potential as pharmaceutical compositions. These derivatives are specifically designed to inhibit serine/threonine and tyrosine kinases, such as PIM1-3 and DYRK1A. The applications of these compounds are notable in treating diseases linked to these kinases, including leukemias, lymphomas, solid tumors, and autoimmune disorders.

2. **Substituted tricyclic benzimidazoles as kinase inhibitors** - In this patent, substituted tricyclic benzimidazoles are disclosed as selective inhibitors of CDK8. These compounds are promising for treating a variety of diseases associated with this kinase, particularly colorectal and melanoma cancers, as well as other solid and hematological malignancies, autoimmune diseases, and inflammatory conditions. The patent also outlines processes for preparing these innovative compounds.

Career Highlights

Katarzyna is currently associated with Selvita S.A., a leading biopharmaceutical company focused on drug discovery and development. Her expertise in medicinal chemistry and commitment to innovation has helped advance the company’s research initiatives and therapeutic targets.

Collaborations

Throughout her career, Katarzyna has collaborated with notable colleagues, including Wojciech Czardybon and Krzysztof Brzózka. These collaborations have fostered a dynamic environment for innovation and led to the successful development of groundbreaking therapeutic solutions.

Conclusion

Katarzyna Wiklik exemplifies the spirit of innovation in the pharmaceutical industry. Her patents reflect a commitment to addressing serious medical conditions through targeted kinase inhibition. With her ongoing contributions, she continues to be an influential figure in the field of medicinal chemistry, paving the way for new treatments and advancements in healthcare.